Hotchkis & Wiley Capital Management
ANIK icon

Hotchkis & Wiley Capital Management’s Anika Therapeutics ANIK Stock Holding History

Hotchkis & Wiley Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-116,400
Closed -$3.52M – 465
2019
Q1 		$3.52M Buy
116,400
+51,910
+80% +$1.78M 0.01% 294
2018
Q4 		$2.17M Sell
64,490
-10,242
-14% -$370K 0.01% 308
2018
Q3 		$3.15M Buy
74,732
+24,981
+50% +$987K 0.01% 306
2018
Q2 		$1.59M Buy
+49,751
New +$2.05M 0.01% 390

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Hotchkis & Wiley Capital Management's ANIK Position: Q2 2019 in Review

Hotchkis & Wiley Capital Management sold out of Anika Therapeutics (ANIK) in Q2 2019, closing a stake of 116,400 shares — an estimated $3.52M sold.

Hotchkis & Wiley Capital Management first reported a position in ANIK in Q2 2018 and held it in 4 quarters. The position peaked at $3.52M in Q1 2019. 165 funds tracked by Wall St. Rank hold ANIK as of Q2 2019.

  • Hotchkis & Wiley Capital Management reported no remaining Anika Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Hotchkis & Wiley Capital Management sold 116,400 Anika Therapeutics shares in Q2 2019, an estimated $3.52M.
  • Hotchkis & Wiley Capital Management first reported a position in Anika Therapeutics in Q2 2018 and held it in 4 quarters.
  • Hotchkis & Wiley Capital Management's Anika Therapeutics position peaked at $3.52M in Q1 2019.
  • 165 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2019.

Based on Hotchkis & Wiley Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.